ReAlta
Norfolk, VA
Short Description
A clinical-stage biopharmaceutical company that develops first-of-its-kind, dual-targeting peptide therapies to treat life-threatening rare diseases and acute inflammatory conditions.
Overview
ReAlta Life Sciences is an innovative biotech firm leading the change in how medicine treats devastating, fast-moving inflammatory disorders. Originating as a scientific breakthrough and research joint venture between EVMS and Children's Hospital of The King's Daughters (CHKD), the company engineers tailored peptides that are headlined by its lead drug compound, pegtarazimod.
By selectively blocking both complement and neutrophil pathways at the initial onset of an immune response, their platform halts tissue damage and brings broad, life-saving control to rare conditions like neonatal Hypoxic Ischemic Encephalopathy (HIE) and acute lung injuries. Backed by over $150 million in total funding, the company is actively advancing its flagship therapeutic platform through rigorous Phase 2 FDA clinical pipelines.